408 results about "Adriamycinol" patented technology

The invention discloses an application of nanometer structure lipid carrier administration system in the antineoplastic drug to reverse the multiple-drug tolerance of tumour cell, which comprises the following parts: solid lipid material, liquid lipid material and antineoplastic drug, wherein the rate of the liquid lipid (such as oleic acid) is 0-30wt%; the solid lipid is selected from monoglyceride; the liquid lipid is oleic acid; the antineoplastic drug is Paclitaxel or adriablastina. The invention has highly effective cell uptaking and cytolymph condensing function with packing molecular target in the antineoplastic drug of cell, which avoids P-glucoprotein in the drug tolerant cytolymph from identifying the antineoplastic drug to reduce exclusion.

The invention discloses a tumor-targeted nanometer drug delivery system for cooperative chemotherapy and photodynamic therapy and a preparation method thereof. The drug delivery system is prepared from carboxymethyl chitosan, folate, a photosensitizer chlorine e6 and adriamycin, wherein the chlorine e6 and the folate are coupled to a carboxymethyl chitosan chain segment through an amido bond, and are loaded to polymer nanoparticles of the adriamycin through an ion exchange method. The nanometer material prepared by the method is high in yield, regular in shape and even in distribution. In-vivo and in-vitro experiments prove that the tumor targeting property of the nanometer preparation can be significantly improved by folate receptor mediation; enrichment on the tumor part is achieved and drug release is controlled. The photosensitizer is capable of effectively reversing the chemotherapy drug resistance and significantly inhibiting the growth of tumors after being irradiated by near-infrared light. Therefore, the related nanometer drug delivery system has good application prospect in the aspect of breast cancer treatment.

The invention provides a macromolecule bonding adriamycin medicine, a nanometer capsule and a preparation method thereof. The bonding medicine is bonded by a block copolymer of poly ethylene glycol-polylactic acid and adriamycin. Firstly, the block copolymer of poly ethylene glycol-polylactic acid is acquired by ring-opening polymerization of aliphatic cyclic esters with poly ethylene glycol, solvent and catalyst being in existence; then a carboxyl end group is transformed by a hydroxyl-terminated; and then with a condensing agent being in existence, the carboxyl end group carries out amidation reaction with the adriamycin; thus acquiring the macromolecule adriamycin bonding medicine. The bonding medicine has amphiphilic property, thus being able to self assembly to prepare the nanometer capsule with a core-shell structure in the water solution. The adriamycin is wrapped inside the capsule to play a role of isolation and protection, which overcomes the deficiencies of short circulation time in vivo, large dosage and severe allergic reaction existing in the current adriamycin preparation. In addition, the nanometer particles are expected to congregate in the blood circulation through the so-called 'enhanced infiltration and retention effect', so as to improve the targeting action of the adriamycin on the tumor location.

The invention provides a nanometer capsule of a macromolecule adriamycin bonding medicine with a targeting function and a preparation method thereof. The nanometer capsule is mixed assembled with two block copolymers of poly ethylene glycol-polylactic acid, wherein the polylactic acid chain end of one block copolymer is connected with adriamycin, with a molar ratio of 98-70 percent in the nanometer capsule, while the poly ethylene glycol chain end of the other block copolymer is connected with lactose, with a molar ratio of 2-30 percent in the nanometer capsule. The adriamycin connected with the polylactic acid chain end is located in the capsule inner core, which is double protected by polylactic acid and poly ethylene glycol and has sustained release function; while the lactose connected with the poly ethylene glycol chain end is located in the outer layer of the capsule, which has targeting function and leads the nanometer capsule preferentially enter the cells carrying the lactose receptors.

The invention provides application of dehydrogenated silibinin diether in the preparation of medicaments for preventing and treating leukemia and relates to medical application of lignin flavone silibinin to the prevention and treatment of chronic myeloid leukemia. Particularly, the invention relates to application of dehydrogenated silibinin diether, of which the seventh bit and the twentieth bit are substituted by 1-butylene, or pharmaceutically acceptable salts thereof in the preparation of medicaments for preventing and treating chronic myeloid leukemia. Natural products of the silibinin are treated by simple steps to synthesize the compound. The pharmacological tests prove that the compound can potently inhibit the in-vitro proliferation of human chronic myeloid leukemia cell strains(K562) and adriamycin drug-resistant strains (K562 / ADR), and the IC50 values are 11.9+ / -1.6 micromoles and 15.9+ / -1.2 micromoles respectively.

The invention discloses an Adriacin or adriacin hydrochloride liposome injection and its preparing process, wherein the injection is prepared from Adriacin or adriacin hydrochloride, neutral phosphatide, negative electric charge phosphatide, cholesterin, anti-oxidant, organic acid, alkali, sugar, buffering agent and water for injection through the steps of preparing margin liposome, homogenizing the liposome, preparing Adriacin or adriacin hydrochloride liposome and their suspension, keeping constant volume, degerming, split charging and conserving.

The invention discloses a tumor-targeted magnetic hydrogel nanoscale medicine delivery system, a construction method and application thereof. The tumor-targeted magnetic hydrogel nanoscale medicine delivery system is prepared by the following steps of: grafting a hydrogel with temperature and pH sensitivity onto the surfaces of ferroferric oxide nanoparticles to form a magnetic hydrogel carrier by a photochemical immobilization method, grafting tumor necrosis factor-alpha, interferon-gamma and a targeted molecular ligand, namely folic acid on the surface of the magnetic hydrogel carrier, and absorbing adriamycin. The system can deliver an antitumor medicine to the periphery of tumor cells by utilizing active targeting, the tumor necrosis factor-alpha, the interferon-gamma and a tumor cellsurface receptor are combined and used for inducing the programmed death of the tumor cells, and the antitumor medicine, namely the adriamycin enters the cells along with the carrier and then is released. Through the experiment, the medicine delivery system has a negligible toxic or side effect, and efficiently inhibits the growth of cancer cells through the coaction mechanism of the tumor necrosis factor-alpha, the interferon-gamma and the antitumor medicine, namely the adriamycin inside and outside the tumor cells.

The invention provides camptothecin-adriamycin prodrug. A structural formula of the prodrug is shown as a formula (I), wherein R1 is camptothecin or derivative group thereof, R2 is one of -CH2- or -O-, R3 is one of -CH2- or -O-, X is one of S or -CH2-, and n1 and n2 are numbers of repeated units, and are integers from 0 to 10. The prodrug can be easily wrapped by amphiphilic polymer to form nanoparticles. The nanoparticles are high in drug carrying efficiency and drug carrying capacity and capable of quickly releasing unmodified camptothecin and adriamycin in the presence of glutathione, and the nanoparticles can be effectively taken in by tumor cells to kill the same. The invention further provides a preparation method of the prodrug, a preparation of the prodrug and application of the prodrug in preparing cancer treating drug.

This invention relates to farmiblastina derivatives, shown as formula, wherein: R1=H or OH, R2 and R3= H or C1-4 hydrocarbon, R4=H, C1-40 saturated or unsaturated hydrocarbon or XR5, wherein X=NH or O, R5=C1-40 saturated or unsaturated hydrocarbon, W=O or NH, R6=H, OH, or O(C1-4 hydrocarbon), R7=H or OH. The invention relates to its preparation and use as medicinal active component thereof.

The invention relates to a preparation method of a dual-targeting drug carrier based on a magnetic metal organic framework material, belonging to the technical field of preparation of bio-medicinal functional materials. The preparation method comprises the following steps: firstly, modifying ferroferric oxide to form dopamine-wrapping ferroferric oxide, and preparing the dual-targeting drug carrier based on the magnetic metal organic framework material by taking dopamine-wrapping ferroferric oxide (Fe3O4@PDA) as the matrix material; and carrying out a series of treatment to obtain an adsorbent, and carrying out selective recognition and separation on adriamycin in an aqueous solution by adopting the adsorbent. The dual-targeting drug carrier based on the magnetic metal organic framework material prepared by adopting the method provided by the invention has good heat stability and very large medicine-carrying capacity, has the acid-base effect, and also has the function of controlling medicine release.

The invention relates to the field of synthesis of pharmaceutical chemistry and particularly relates to a specific method for ferroferric oxide, PDA-coated ferroferric oxide, pegylation and final drug-loading and various steps. A preparation method of pegylated polydopamine-coated drug-loaded magnetic nanoparticles specifically comprises the following steps: (1) synthesizing ferroferric oxide by adopting an alkaline coprecipitation method; (2) carrying out auto-polymerization on dopamine under an alkaline condition in the presence of the ferroferric oxide; (3) pegylating PDA-coated magnetic nanoparticles; and (4) carrying anti-cancer drug adriamycin to the magnetic nanoparticles by using hydrophobic interaction. The obtained composite nanodrug delivery system has the advantages of targeting delivery, high drug loading capacity and good biocompatibility.

The invention belongs to the fields of supramolecular polymer polymer chemistry and drop formation control, and particularly relates to supramolecular hydrogel microsphere modified with cyclodextrin water-solubility polymer and adamantine water-solubility polymer and formed by assembling subjective and objective bodies in a liquid drop, and a preparation method and application thereof. The first purpose of the invention is to provide novel supramolecular hydrogel microsphere formed by assembling subjective and objective bodies and a preparation method thereof method, the second purpose of the invention is to adopt liquid drop as a template to realize supramolecular assembly and achieve uniform particle size and controllable dimension of the supramolecular hydrogel microsphere, and the third purpose of the invention is to provide application of the type of supramolecular hydrogel microsphere in adriacin doxorubicin and taxol water-solubility antitumor drug sustained release, so as to achieve the purpose that a drug can keep a high concentration level for a long time.

The invention relates to a pH-sensitive anticancer prodrug and a preparation method as well as application thereof, which belongs to the field of medicine and chemical industry. The technical problem to be solved is to provide the pH-sensitive anticancer prodrug, and the anticancer prodrug has highest solubility when the pH value is between 4 and 6, can nearly not be dissolved when the pH value is less than 3 or more than 7, and almost does not release adriamycin during the circulation due to small solubility particularly when circulating in blood (the pH value is approximately equal to 7.4), thereby having small toxic side effect. The pH-sensitive anticancer prodrug is a conjugate obtained by coupling the adriamycin and pectin with a molecular weight of between 71,000 and 400,000 through a chemical bond. The pH-sensitive anticancer prodrug is obtained by the following steps: a pectin aqueous solution and an adriamycin aqueous solution are added with a dehydrating agent to react under the condition that the pH value is between 6 and 8, and then are dialyzed and condensed.

The invention belongs to the technical field of composite medicine materials as well as a preparation method and application thereof, more particularly discloses a nanoparticle for embedding medicinal Adriamycin. The nanoparticle has a core-shell type structure with an inner core embedded by an outer shell, wherein the inner core is embedded medicinal adriamycin, and the material for the outer shell is silicon dioxide; and the preparation method of the nanoparticle comprises the following steps of: evenly mixing cyclohexane, a surfactant and n-hexylalcohol, adding a sodium fluoride solution into the mixed solution after being evenly mixed to form a reverse-phase microemulsion; adding adriamycin and tetraethoxysilane into the reverse-phase microemulsion, and reacting to obtain a nanoparticle microemulsion system for embedding the adriamycin; adding a silylanization reagent containing functional groups into the microemulsion system, stirring for reacting, adding ethanol and demulsifying, centrifuging and then preparing the nanoparticle for embedding the medicinal adriamycin and modifying the functional groups. The nanoparticle embedding for the adriamycin has good stability, good biocompatibility, long slow-release time, large drug-loading rate, high medicine packaging rate, and the like, and has application prospect in the fields of tumor imaging and treatment.

The present invention provides one kind of adriamycin derivative in the structure as shown. The modified adriamycin derivative, pharmacological experiment shows, has obvious antitumor activity, as well as cytotoxicity lower than that of adriamycin, obvious targeting property, stable quality and high controllability.

The invention discloses a carbon nanometer tube decorated by polyethyleneimine and a compound of plasmid DNA thereof. The plasmid DNA adopted in the invention comprises P53DNA, green fluorescent protein expression (JPC) and unmethylated oligomerization deoxynucleotide plasmid DNA. The carbon nanometer tube decorated by the polyethyleneimine and the compound of the plasmid DNA have the advantages of high transfection efficiency and less toxicity to cells; in particular, when the concentration is 30 g / ml, the transfection efficiency is larger than 90 percent, and the validity of the cells is larger than 80 percent. The carbon nanometer tube decorated by the polyethyleneimine and the compound of the plasmid DNA have wide application prospect during the process of preparing medicaments for remedying genes outside transfecting osteosarcoma cell bodies and in animal bodies; and the carbon nanometer tube decorated by the polyethylene imine / the plasmid DNA / an adriacin nanometer compound also have wide application during the process of preparing medicaments for restraining the growth of tumor.

The invention discloses a preparation method of a photo-thermal and chemotherapeutic precise synergic antitumor temperature-sensitive gold nanocage hydrogel drug carrying system. The preparation method comprises the following steps of: 1) mixing a gold nanocage with a high-temperature ligand, stirring and incubating the mixture and performing centrifugation to obtain a high-temperature ligand-modified gold nanocage, wherein the high-temperature ligand is a chain-like temperature-sensitive polymer containing a disulfide bond, and the phase change temperature of the high-temperature ligand is 39-50 DEG C; 2) dispersing the high-temperature ligand-modified gold nanocage obtained in the step 1) in an ammonium sulfate solution, stirring and centrifugalizing the mixture, dispersing a solid with an aqueous solution of adriamycin, and leaving the mixture to stand in a dark place to obtain a drug-carrying gold nanocage; and 3) mixing the drug-carrying gold nanocage obtained on the step 2) with a low-temperature ligand, and stirring and incubating the mixture and performing centrifugation to obtain the photo-thermal and chemotherapeutic precise synergic antitumor temperature-sensitive gold nanocage hydrogel drug carrying system, wherein the low-temperature ligand is a chain-like temperature-sensitive polymer containing a disulfide bond, and the phase change temperature of the low-temperature ligand is 26-35 DEG C.

The invention discloses a preparation method and application of carbon dots from beer as a main raw material. In the method, the carbon dots are separated and purified through sephadex gel chromatography and then are collected. The carbon dots can directly be used in living cell fluorescent imaging, and in addition, the carbon dots are mixed and stirred with adriamycin in water to support the adriamycin onto the carbon dots, which can be used for killing tumor cells. The beer carbon dots are low in cost, low in toxicity and simple in method, has good water solubility when the adriamycin is supported thereon, and can be used in the fields of tumor fluorescent markers and treatment as a fluorescent medicine carrier.

The invention discloses a trgeting and slow-release antineoplastic medicine nanoparticle with amphiphilic polyurethane as a carrier and a preparation method thereof. The nanoparticle is of a nucleus-shell structure provided with two shell layers; a hydrophilic section of amphiphilic polyurethane serves as the shell layer, and a hydrophobic section serves as the nucleus; the nucleus covers the medicines; a functional molecule exposes from the surface of the shell layer of the nanoparticle; organo-siloxane can be hydrolyzed to form another shell layer between the hydrophilic section and the hydrophobic section; the medicines include capecitabine, adriamycin and paclitaxel; the functional molecule is folic acid; and organo-siloxane is tetramethoxysilane. The targeting and slow-release antineoplastic medicine nanoparticle with amphiphilic polyurethane as the carrier has the characteristics that degradable polymer materials are used as the medicine release-control preparations, which enables the medicine to act on a specified wound position with the minimum dosage; and the medicine release rate can be optimized to improve the treatment effect as well as reduce the toxic and side effects.

The invention relates to the technical field of medicines. The invention relates to the field of biomimetic drugs, in particular to biomimetic drug-loaded nanoparticles targeting brain tumor and a preparation method and application thereof, and particularly relates to adriamycin-loaded polyglutamic acid biomimetic nanoparticles which target brain tumor cells and is coated by human brain glioma U87cell membranes and a preparation method and application thereof in drugs for treating brain tumor diseases. The preparation method of the biomimetic drug-loaded nanoparticles targeting brain tumor comprises the following steps: preparing adriamycin-loaded polyglutamic acid nanoparticles, and coating the surfaces of the nanoparticles with the human brain glioma U87 cell membranes to form the stable biomimetic drug-loaded nanoparticles. Therefore, higher encapsulation efficiency and better slow release performance are realized, the targeting property of the nano drug delivery system is improved, the biomimetic drug delivery nanoparticles penetrating through the blood-brain barrier can be more effectively gathered in a brain tumor area, and the effect of treating brain tumors by chemotherapeutic drugs is improved.

The invention relates to a method for preparing a dual-function targeting quantum dot lipidosome. The method comprises the following steps: preparing a single quantum dot lipidosome: dissolving phospholipid, cholesterol, methoxy polyethylene glycol-phospholipid complex and NRP-1 ligand polypeptide polyethylene glycol phospholipid complex into chloroform to obtain a uniform lipid membrane, and drying the chloroform by evaporation; dissolving in an ammonium sulfate solution of quantum dots, and oscillating to obtain lipidosome suspension; extruding, and diluting with normal saline to obtain an active targeting lipidosome containing the quantum dots; adding the active targeting lipidosome containing the quantum dots into an adriamycin normal saline solution, and treating in a water bath for 20 minutes at the temperature of 60 DEG C; and diluting with normal saline through a SephadexG-50 gel column, removing free medicaments, and thus obtaining the dual-function targeting quantum dot lipidosome. The lipidosome prepared by the method can be used for marking and treating glioma cells.

The present invention discloses one kind of folic acid receptor mediated targeting chitosan carrier and its preparation process and application. The present invention has folic acid and its derivative as targeting agent, chitosan and its derivative as carrier and chemotherapeutic medicine adriamycin and other synergistic antisense nucleic acid as acting medicine to raise the stability and targeting property of the administration system. Therefore, the nanometer carrier has wide application foreground in treating tumor.

The invention discloses adriamycin-containing nanometer medicament microspheres, which comprises adriamycin, nanoparticles, a polymer and medicinal auxiliary materials. The invention further provides a preparation method of the microspheres. The method comprises the following steps of: preparing adriamycin and the medicinal auxiliary materials into a nanometer medicament; adding the nanometer medicament into a polymer-containing organic solvent mixed solution for emulsifying; adding a nanometer medicament-in-oil mixed suspension into a water mixed suspension containing nanoparticles or containing nanoparticles and a surfactant for emulsifying to obtain an oil-in-nanoparticle mixed suspension-nanometer medicament-in-oil compound emulsion; and curing the obtained compound emulsion, and centrifugally collecting microspheres. An appropriate polymer material and an appropriate microsphere preparation method are selected, the prepared microspheres have high envelop rate, and a layer of self-assembled nanoparticles on the surfaces of the microspheres has the effects of improving cell adhesion and reducing inflammation and microencapsulation caused by local excessive acid and hydrophobic materials. The method disclosed by the invention can be applied to preparation of other medicament slow release or controlled release microspheres.

The invention discloses a method for preparing a nanometer system for multi-model diagnosis and treatment integration. The method comprises the following steps: adopting an in-situ growth nanogold modified rare-earth upconversion nanoparticle method to perform ligand exchange modification on oil-soluble upconversion luminescence nanoparticles of citric acid with a core-shell structure to be water-soluble, and performing citric acid ligand modification on the surfaces of the nanoparticles; uniformly growing nanogold particles on the surface through an in-situ crystal growth method so as to obtain in-situ growth nanogold modified upconversion luminescence nanoparticles; and linking polyethylene glycol-adriamycin hydrochloride containing hydrazone bonds and thiol onto the nanogold surface, thereby obtaining the rare-earth upconversion nanometer system. The invention further provides the nanometer system and application thereof. The nanometer system provided by the invention is uniform in size, high in stability and high in biocompatibility, has the effects of chemotherapy and photo-thermal physiotherapy and can be applied to the fields of upconversion fluorescence imaging, magnetic resonance imaging, anti-cancer drug delivery, photo-thermal physiotherapy of cancers and the like.

The invention discloses an acid-responsive nanometer micelle for drug loading, a preparation method and an application thereof. The nano-micelles were self-assembled from hydrophilic segment polyethylene glycol (PEG) and hydrophobic segment pH-sensitive polyaspartyl diisopropylethylenediamine / di-n-butylethylenediamine (PAsp (DIP / DBA)). The nano-micelles can prolong the drug circulation time, aggregate in the tumor site, increase the local drug concentration, and respond to the micro-acid environment of the tumor tissue. As a drug carrier of stimulation response, the nano-micelles can rapidly release the loaded chemotherapeutic drug adriamycin in the tumor site, and play a significant anti-tumor effect. At the same time, the nano-micelles loaded with magnetic resonance contrast agent superparamagnetic iron oxide can be used for tumor magnetic resonance imaging and monitoring drug uptake and aggregation. This method utilizes nano-drug aggregation at tumor site and acid responsiveness ofcarrier to realize rapid drug release to improve tumor therapeutic effect, and endows nano-micellar MRI visualization function, which provides a promising innovative strategy for cancer diagnosis andtreatment, and has broad application prospects.

The invention discloses a tussah silk protein adriamycin sustained release microsphere and a preparation method thereof. The tussah silk protein adriamycin sustained release microsphere takes calcium ions as an inducer, natural tussah silk proteins as a shell and adriamycin as nano particles of a core, is uniform in distribution of particle sizes, has the diameter of about 500 nanometers and is biodegradable. According to the tussah silk protein adriamycin sustained release microsphere and the preparation method disclosed by the invention, as the preparation environment of the tussah silk protein adriamycin sustained release microsphere is in a neutral and normal pressure and temperature state, an organic solvent is avoided, and the utilization degree of a medicament is increased; with the tussah silk proteins as an embedding material of the adriamycin, the tussah silk protein adriamycin sustained release microsphere has an RGD sequence and is capable of promoting cells to identify the tussah silk protein adriamycin sustained release microsphere and improving the targeting property of an adriamycin medicament; compared with free adriamycin, the adriamycin embedded in the tussah silk protein microsphere is obvious in sustained release property, expresses pH sensitivity, is obvious in sustained release effect in the environment with a pH value of 5.2, is small in releasing speed under the neutral condition, is convenient for a medicament to be released after entering cancer cells and is capable of remarkably lowering the toxic and side effects in normal cells.

The invention discloses a target antitumor prodrug which is mediated by a folic acid-polypeptide composite; the constructive general formula of the invention is X-ASGP-Cyt'. The invention also discloses a typical prodrug of folic acid-polypeptide-adriamycin. Meanwhile, the invention discloses the preparation method of the prodrug. Specificity substrate alanyl-seryl-glycyl-proline (ASGP) polypeptide is utilized as connexin, free carboxyl is used for modifying the free amino-group of adriamycin and other antitumor drugs, and the free amino-group is connected to the carboxyl of folic acid so as to synthesize the enzyme activation type target antitumor prodrug carrying polypeptide, which can be selectively hydrolyzed around tumorous interstitial cells, and folic acid, which has high affinity with the folate receptors on tumorous interstitial cells, thus accelerating the active enrichment of the antitumor drug toward specific tumor tissues and achieving the aim of hydrolyzing and releasing the target cytotoxia drug surrounding tumor tissues.

The invention discloses an aptamer for recognizing adriamycin-resistant breast cancer cells. The aptamer can be a single-stranded DNA molecule. Particularly, the aptamer can be an aptamer (1) formed by nucleotide molecules as shown in SEQ ID No. 1, an aptamer (2) formed by nucleotide molecules as shown in SEQ ID No. 2, an aptamer (3) formed by nucleotide molecules as shown in SEQ ID No. 3, an aptamer (4) formed by nucleotide molecules as shown in SEQ ID No. 4, an aptamer (5) formed by nucleotide molecules as shown in SEQ ID No. 5 and an aptamer (6) formed by nucleotide molecules as shown in SEQ ID No. 6. By adopting the aptamer disclosed by the invention, the resistance to medicines of tumors can be monitored in real time according to molecular response signals under the condition that the medicine resistance mechanism is unknown so that the treatment scheme can be changed timely and the success rate of chemotherapy can be increased.

The invention relates to a preparation method and an application of a gold nano-star based multi-functional anti-tumor target diagnostic treatment medicine. The medicine can be used for effectively solving the problems of large toxic and side effects, poor biocompatibility and poor target of existing anti-tumor medicines. The preparation method comprises the following steps: firstly, modifying the structure of a gold nano-star carrier and reacting with a sulfydryl-containing amino compound to obtain an amino modified gold nano-star solution; then, performing an amidation reaction on the amino modified gold nano-star and a hydrazine bond compound for activating carboxyl to generate a modified gold nano-star solution of which the terminal is connected with a hydrazine bond; performing a chemical reaction on the gold nano-star solution with carbonyl-containing adriamycin by utilizing the hydrazine body at the terminal of the gold nano-star solution to form a pH sensitive hydrazone bond compound; and finally reacting the compound with thiolate NGR by virtue of a sulfur-gold bond. The gold nano-star based multi-functional anti-tumor target diagnostic treatment medicine has excellent physicochemical stability, simple in preparation process, rich in raw material source, low in cost and small in toxic and side effects, can be used for effectively inhibiting reproduction of tumor cells, and is an innovation on anti-tumor target diagnostic treatment medicines.